Drug Repurposing a Compelling Cancer Strategy with Bottomless Opportunities: Recent Advancements in Computational Methods and Molecular Mechanisms

Overview

Journal Indian J Pharmacol

Specialty Pharmacology

Date 2023 Nov 6

PMID 37929411

Authors

Rasmita Dash

Madhulika Yadav

Jyotirmaya Biswal

Shrabani Samanta

Tripti Sharma

Sujata Mohapatra

Affiliations

Soon will be listed here.

Abstract

Drug discovery has customarily focused on a de novo design approach, which is extremely expensive and takes several years to evolve before reaching the market. Discovering novel therapeutic benefits for the current drugs could contribute to new treatment alternatives for individuals with complex medical demands that are safe, inexpensive, and timely. In this consequence, when pharmaceutically yield and oncology drug efficacy appear to have hit a stalemate, drug repurposing is a fascinating method for improving cancer treatment. This review gathered about how in silico drug repurposing offers the opportunity to quickly increase the anticancer drug arsenal and, more importantly, overcome some of the limits of existing cancer therapies against both old and new therapeutic targets in oncology. The ancient nononcology compounds' innovative potential targets and important signaling pathways in cancer therapy are also discussed. This review also includes many plant-derived chemical compounds that have shown potential anticancer properties in recent years. Here, we have also tried to bring the spotlight on the new mechanisms to support clinical research, which may become increasingly essential in the future; at the same time, the unsolved or failed clinical trial study should be reinvestigated further based on the techniques and information provided. These encouraging findings, combined together, will through new insight on repurposing more non-oncology drugs for the treatment of cancer.

References

Hasan M, Leak R, Stratford R, Zlotos D, Witt-Enderby P . Drug conjugates-an emerging approach to treat breast cancer. Pharmacol Res Perspect. 2018; 6(4):e00417. PMC: 6032357. DOI: 10.1002/prp2.417. View

Desai A, Gyawali B . Financial toxicity of cancer treatment: Moving the discussion from acknowledgement of the problem to identifying solutions. EClinicalMedicine. 2020; 20:100269. PMC: 7152810. DOI: 10.1016/j.eclinm.2020.100269. View

Hodos R, Kidd B, Shameer K, Readhead B, Dudley J . In silico methods for drug repurposing and pharmacology. Wiley Interdiscip Rev Syst Biol Med. 2016; 8(3):186-210. PMC: 4845762. DOI: 10.1002/wsbm.1337. View

Notta F, Mullighan C, Wang J, Poeppl A, Doulatov S, Phillips L . Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature. 2011; 469(7330):362-7. DOI: 10.1038/nature09733. View

Ekinci E, Rohondia S, Khan R, Dou Q . Repurposing Disulfiram as An Anti-Cancer Agent: Updated Review on Literature and Patents. Recent Pat Anticancer Drug Discov. 2019; 14(2):113-132. DOI: 10.2174/1574892814666190514104035. View

Porta C, Paglino C, Mosca A . Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol. 2014; 4:64. PMC: 3995050. DOI: 10.3389/fonc.2014.00064. View

Thompson D, OMara T, Glubb D, Painter J, Cheng T, Folkerd E . CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer. Endocr Relat Cancer. 2015; 23(2):77-91. PMC: 4697192. DOI: 10.1530/ERC-15-0386. View

Warita K, Warita T, Beckwitt C, Schurdak M, Vazquez A, Wells A . Statin-induced mevalonate pathway inhibition attenuates the growth of mesenchymal-like cancer cells that lack functional E-cadherin mediated cell cohesion. Sci Rep. 2014; 4:7593. PMC: 4274516. DOI: 10.1038/srep07593. View

Lamb J, Crawford E, Peck D, Modell J, Blat I, Wrobel M . The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006; 313(5795):1929-35. DOI: 10.1126/science.1132939. View

10.

Grilli R, Oxman A, Julian J . Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?. J Clin Oncol. 1993; 11(10):1866-72. DOI: 10.1200/JCO.1993.11.10.1866. View

11.

Siddiqui F, Prakasam G, Chattopadhyay S, Rehman A, Padder R, Ansari M . Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1α inhibition. Sci Rep. 2018; 8(1):8323. PMC: 5974195. DOI: 10.1038/s41598-018-25524-3. View

12.

Dey Ray S, Dewanjee S . Isolation of a new triterpene derivative and in vitro and in vivo anticancer activity of ethanolic extract from root bark of Zizyphus nummularia Aubrev. Nat Prod Res. 2014; 29(16):1529-36. DOI: 10.1080/14786419.2014.983921. View

13.

Mesmar J, Fardoun M, Abdallah R, Dhaheri Y, Yassine H, Iratni R . Attenuates the Malignant Phenotype of Human Pancreatic Cancer Cells: Role of ROS. Molecules. 2021; 26(14). PMC: 8307183. DOI: 10.3390/molecules26144295. View

14.

Dolan M . Capturing cancer initiating events in OncoCL, a cancer cell ontology. AMIA Jt Summits Transl Sci Proc. 2015; 2014:41. PMC: 4333700. View

15.

Dash R, Yadav M, Biswal J, Chandra A, Kumar Goel V, Sharma T . Modeling of chitosan modified PLGA atorvastatin-curcumin conjugate (AT-CU) nanoparticles, overcoming the barriers associated with PLGA: An approach for better management of atherosclerosis. Int J Pharm. 2023; 640:123009. DOI: 10.1016/j.ijpharm.2023.123009. View

16.

Sleire L, Forde H, Netland I, Leiss L, Skeie B, Enger P . Drug repurposing in cancer. Pharmacol Res. 2017; 124:74-91. DOI: 10.1016/j.phrs.2017.07.013. View

17.

Paananen J, Fortino V . An omics perspective on drug target discovery platforms. Brief Bioinform. 2019; 21(6):1937-1953. PMC: 7711264. DOI: 10.1093/bib/bbz122. View

18.

Li X, Xu H, Dai X, Zhu Z, Liu B, Lu X . Enhanced in vitro and in vivo therapeutic efficacy of codrug-loaded nanoparticles against liver cancer. Int J Nanomedicine. 2012; 7:5183-90. PMC: 3464082. DOI: 10.2147/IJN.S34886. View

19.

Nagahama K, Utsumi T, Kumano T, Maekawa S, Oyama N, Kawakami J . Discovery of a new function of curcumin which enhances its anticancer therapeutic potency. Sci Rep. 2016; 6:30962. PMC: 4967984. DOI: 10.1038/srep30962. View

20.

Desai A, Qazi G, Ganju R, El-Tamer M, Singh J, Saxena A . Medicinal plants and cancer chemoprevention. Curr Drug Metab. 2008; 9(7):581-91. PMC: 4160808. DOI: 10.2174/138920008785821657. View